124 related articles for article (PubMed ID: 31248982)
1. Benzoquinone, a leukemogenic metabolite of benzene, catalytically inhibits the protein tyrosine phosphatase PTPN2 and alters STAT1 signaling.
Duval R; Bui LC; Mathieu C; Nian Q; Berthelet J; Xu X; Haddad I; Vinh J; Dupret JM; Busi F; Guidez F; Chomienne C; Rodrigues-Lima F
J Biol Chem; 2019 Aug; 294(33):12483-12494. PubMed ID: 31248982
[TBL] [Abstract][Full Text] [Related]
2. Macrophages Compensate for Loss of Protein Tyrosine Phosphatase N
Hering L; Katkeviciute E; Schwarzfischer M; Niechcial A; Riggs JB; Wawrzyniak M; Atrott K; van de Sande M; Lang S; Becher B; Rogler G; Scharl M; Spalinger MR
Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34201918
[TBL] [Abstract][Full Text] [Related]
3. PTPN2 Deficiency Enhances Programmed T Cell Expansion and Survival Capacity of Activated T Cells.
Flosbach M; Oberle SG; Scherer S; Zecha J; von Hoesslin M; Wiede F; Chennupati V; Cullen JG; List M; Pauling JK; Baumbach J; Kuster B; Tiganis T; Zehn D
Cell Rep; 2020 Jul; 32(4):107957. PubMed ID: 32726622
[TBL] [Abstract][Full Text] [Related]
4. PTPN2 inhibits the proliferation of psoriatic keratinocytes by dephosphorylation of STAT3.
Liu S; Liu F; Zhang Z; Zhuang Z; Chen Y
Cell Biochem Funct; 2024 Mar; 42(2):e3947. PubMed ID: 38379221
[TBL] [Abstract][Full Text] [Related]
5. PTPN2 Regulates Metabolic Flux to Affect β-Cell Susceptibility to Inflammatory Stress.
Kim YK; Kim YR; Wells KL; Sarbaugh D; Guney M; Tsai CF; Zee T; Karsenty G; Nakayasu ES; Sussel L
Diabetes; 2024 Mar; 73(3):434-447. PubMed ID: 38015772
[TBL] [Abstract][Full Text] [Related]
6. Small-molecule PTPN2 Inhibitors Sensitize Resistant Melanoma to Anti-PD-1 Immunotherapy.
Zhu Z; Tang R; Huff S; Kummetha IR; Wang L; Li N; Rana TM
Cancer Res Commun; 2023 Jan; 3(1):119-129. PubMed ID: 36968224
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of the type 1 diabetes candidate gene PTPN2 aggravates TNF-α-induced human beta cell dysfunction and death.
Roca-Rivada A; Marín-Cañas S; Colli ML; Vinci C; Sawatani T; Marselli L; Cnop M; Marchetti P; Eizirik DL
Diabetologia; 2023 Aug; 66(8):1544-1556. PubMed ID: 36988639
[TBL] [Abstract][Full Text] [Related]
8. Discovery of PVD-06 as a Subtype-Selective and Efficient PTPN2 Degrader.
Hu L; Li H; Qin J; Yang D; Liu J; Luo X; Ma J; Luo C; Ye F; Zhou Y; Li J; Wang M
J Med Chem; 2023 Nov; 66(22):15269-15287. PubMed ID: 37966047
[TBL] [Abstract][Full Text] [Related]
9. Efficient CRISPR/Cas9 Disruption of Autoimmune-Associated Genes Reveals Key Signaling Programs in Primary Human T Cells.
Anderson W; Thorpe J; Long SA; Rawlings DJ
J Immunol; 2019 Dec; 203(12):3166-3178. PubMed ID: 31722988
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and structure-activity optimization of azepane-containing derivatives as PTPN2/PTPN1 inhibitors.
Zheng J; Zhang Z; Ding X; Sun D; Min L; Wang F; Shi S; Cai X; Zhang M; Aliper A; Ren F; Ding X; Zhavoronkov A
Eur J Med Chem; 2024 Apr; 270():116390. PubMed ID: 38604096
[TBL] [Abstract][Full Text] [Related]
11. Pan-cancer analysis revealing that PTPN2 is an indicator of risk stratification for acute myeloid leukemia.
Wang X; Wu S; Sun L; Jin P; Zhang J; Liu W; Zhan Z; Wang Z; Liu X; He L
Sci Rep; 2023 Oct; 13(1):18372. PubMed ID: 37884566
[TBL] [Abstract][Full Text] [Related]
12. Strain-dependent differences in bone development, myeloid hyperplasia, morbidity and mortality in ptpn2-deficient mice.
Wiede F; Chew SH; van Vliet C; Poulton IJ; Kyparissoudis K; Sasmono T; Loh K; Tremblay ML; Godfrey DI; Sims NA; Tiganis T
PLoS One; 2012; 7(5):e36703. PubMed ID: 22590589
[TBL] [Abstract][Full Text] [Related]
13. Protein tyrosine phosphatase non-receptor type 2 as the therapeutic target of atherosclerotic diseases: past, present and future.
Tang XE; Cheng YQ; Tang CK
Front Pharmacol; 2023; 14():1219690. PubMed ID: 37670950
[TBL] [Abstract][Full Text] [Related]
14. X-CHIME enables combinatorial, inducible, lineage-specific and sequential knockout of genes in the immune system.
LaFleur MW; Lemmen AM; Streeter ISL; Nguyen TH; Milling LE; Derosia NM; Hoffman ZM; Gillis JE; Tjokrosurjo Q; Markson SC; Huang AY; Anekal PV; Montero Llopis P; Haining WN; Doench JG; Sharpe AH
Nat Immunol; 2024 Jan; 25(1):178-188. PubMed ID: 38012416
[TBL] [Abstract][Full Text] [Related]
15. Benzene and Its Principal Metabolites Modulate Proinflammatory Cytokines and Growth Factors in Human Epidermal Keratinocyte Cultures.
Wilmer JL; Simeonova PP; Germolec DR; Luster MI
In Vitro Toxicol; 1997 Dec; 10(4):429-436. PubMed ID: 21160545
[TBL] [Abstract][Full Text] [Related]
16. The Inhibitors of Protein Tyrosine Phosphatase Nonreceptor Type 2 (PTPN2) as Potential Enhancers of Cancer Immunotherapy and Type 1 (PTPN1) as Treatment of Metabolic Diseases.
Abdel-Magid AF
ACS Med Chem Lett; 2022 Jan; 13(1):19-21. PubMed ID: 35059117
[No Abstract] [Full Text] [Related]
17. PTPN2 regulates the generation of exhausted CD8
LaFleur MW; Nguyen TH; Coxe MA; Miller BC; Yates KB; Gillis JE; Sen DR; Gaudiano EF; Al Abosy R; Freeman GJ; Haining WN; Sharpe AH
Nat Immunol; 2019 Oct; 20(10):1335-1347. PubMed ID: 31527834
[TBL] [Abstract][Full Text] [Related]
18. PTPN2 phosphatase deletion in T cells promotes anti-tumour immunity and CAR T-cell efficacy in solid tumours.
Wiede F; Lu KH; Du X; Liang S; Hochheiser K; Dodd GT; Goh PK; Kearney C; Meyran D; Beavis PA; Henderson MA; Park SL; Waithman J; Zhang S; Zhang ZY; Oliaro J; Gebhardt T; Darcy PK; Tiganis T
EMBO J; 2020 Jan; 39(2):e103637. PubMed ID: 31803974
[TBL] [Abstract][Full Text] [Related]
19. PTPN2 regulates the activation of KRAS and plays a critical role in proliferation and survival of KRAS-driven cancer cells.
Huang Z; Liu M; Li D; Tan Y; Zhang R; Xia Z; Wang P; Jiao B; Liu P; Ren R
J Biol Chem; 2020 Dec; 295(52):18343-18354. PubMed ID: 33122197
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
